Drugs / LBL-024 for Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07390383 | Apr 2026 → May 2028 expected | high grade malignant neoplasm | Nanjing Leads Biolabs Co.,Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LBL-024 for Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07390383 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT07390383 ↗ |